Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage, CA

Research site

(Unclaimed)

Location

34490 Bob Hope Drive, Rancho Mirage, California, United States of America

Site insights

Top conditions

Top treatments

Gemcitabine

Carboplatin

Docetaxel

Paclitaxel

Avelumab

Azacitidine

Cemiplimab

Pembrolizumab

Lenalidomide

Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 41 total trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug: Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Drug: Fuzuloparib , Abiraterone acetate and Prednisone

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting

Part 2：B-cell Malignancies

Part 1：r/r B-cell Malignancies

Drug: Orelabrutinib (ICP-022)

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling

Advanced Non-Small Cell Lung Cancer

Drug: cemiplimab

Drug: Placebo

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

Enrolling

Non-small Cell Lung Cancer

Drug: Pemetrexed

Drug: fianlimab

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...

Active, not recruiting

Non Small Cell Lung Cancer

Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab

Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tum...

Enrolling

Microsatellite Instability

Melanoma

Drug: N-803 + Atezolizumab + PD-L1 t-haNK

Drug: N-803 + Pembrolizumab